GLP‑1 use surges
About one in eight U.S. adults now report taking anti‑obesity drugs such as Wegovy or Zepbound, highlighting intense consumer demand for these medicines. (telegraphherald.com) Eli Lilly is expanding an oral GLP‑1 pill, orforglipron (marketed as Foundayo), into roughly 40 countries including India — a shift toward pills from injections. (news9live.com) Experts in the reporting say these drugs are most effective when combined with healthy eating, regular exercise, and behavior change rather than used alone. (telegraphherald.com)
About one in eight United States adults now say they are currently taking a glucagon-like peptide 1 drug such as Wegovy or Ozempic. (kff.org) KFF reported in November 2025 that 12% of adults were current users, up 6 percentage points from 18 months earlier, and 18% said they had ever taken one. Half of current or recent users said the drugs were difficult to afford. (kff.org) These medicines copy gut hormones that help people feel full and lower blood sugar. The class includes semaglutide, sold as Ozempic and Wegovy, and tirzepatide, sold as Mounjaro and Zepbound. (niddk.nih.gov) The market is also shifting from shots to pills. Eli Lilly said on April 1, 2026, that the Food and Drug Administration approved Foundayo, the brand name for orforglipron, as a once-daily oral glucagon-like peptide 1 pill for adults with obesity or overweight with weight-related complications. (prnewswire.com) Indian outlets reported on April 13, 2026, that Lilly plans to launch orforglipron in about 40 countries, including India, after the United States approval. That would widen access in markets where weekly injections have been expensive, scarce, or harder to use. (news9live.com) Doctors and federal health agencies do not present these drugs as a stand-alone fix. The National Institute of Diabetes and Digestive and Kidney Diseases says people struggling with weight still need a healthy eating plan and regular physical activity for long-term weight loss and maintenance. (niddk.nih.gov) Mayo Clinic dietitians make the same point in plainer terms: the drugs can reduce hunger, but lasting results still depend on food habits, movement, sleep, and other behavior changes. They also note that eligibility is usually tied to body mass index and weight-related health conditions, not simple cosmetic use. (mayoclinic.org) The surge in use has exposed a split in the market. Demand is broad, but KFF found cost remains a barrier even as more adults seek prescriptions for diabetes, heart disease, or weight loss. (kff.org) What comes next is less about whether Americans want these drugs and more about which version they can get: a weekly injection, a daily pill, or no treatment at all if the price stays out of reach. (kff.org)
